Bengaluru, Mary 12, 2016: Ken Research introduces its latest publication on, “Market Research Report on Aceglutamide in China, 2010-2019” which offers detailed insights into the changing trends within the Chinese pharmaceuticals industry. The focus is primarily on the increasing demand for drugs that can treat nerve cell damage such as Aceglutamide. A detailed profile of Aceglutamide including its sales position, market share and pricing in the Chinese market is also present in the investigative report. Furthermore, profiles of leading players selling Aceglutamide in the Chinese market are also included.
With increased use of technology and rapid urbanization, the lifestyle of people living across the world has changed for the better. Additionally, the aspirations and pressure to maintain a certain quality of life has forced people to work beyond what is good for their mental and physical well-being. As a result, a large proportion of the working age population is suffering from problems associated with nerve cell damage. The damage of single neural limitation is a common cause of trauma, while multiple single neuropathy occurs secondary to collagen vascular disease, according to the Research Analyst, Ken Research.
One of the popular drugs for treating nerve cell damage is Aceglutamide. It refers to acetyl compounds of glutamine, which is capable to improve metabolism of nerve cell and to maintain nerve-stress and lower blood amine. It can also be used for treating traumatic brain injury coma, hepatic coma, hemiplegia, paraplegia, polio sequelae, sequelae of traumatic brain injury, mental deterioration, nervous headache and low back pain through Blood Brain Barrier(BBB).
The sales of Aceglutamide in China have been increasing in past few years. In fact, by the end of 2020, the incidence of nerve cell damage related problem amongst Chinese pharmaceutical industry is expected to grow manifolds resulting in a direct positive impact on the sales of Aceglutamide. Historically, from 2011 to 2014, the market scale of Aceglutamide in China was increasing, at a CAGR of about 23.2%. Since 2014, drug sales volume has exceeded CNY 40.0 million. In next few years, it is predicted that the demand for central stimulant drugs in Chinese market will continue to increase, which will promote the market size of Aceglutamide.
Global Aceglutamide Market
The human body’snervous system is responsible for connecting the brain with the rest of the body. Any malfunctioning in the peripheral nerves is termed as nerve cell damage and the etiology of this medical condition includes dietary deficiencies, diabetes, chronic kidney disease, alcohol abuse and any hereditary disease, according to the Research Analyst, Ken Research.
Corporate Comm India (CCI Newswire)
